Skip to main content
Critical Care logoLink to Critical Care
. 2021 Jun 27;25:220. doi: 10.1186/s13054-021-03646-x

Evaluation of right ventricular function and driving pressure with blood gas analysis could better select patients eligible for VV ECMO in severe ARDS

Matthieu Petit 1,2,, Armand Mekontso-Dessap 3,4,5, Paul Masi 3,4, Annick Legras 7, Philippe Vignon 6, Antoine Vieillard-Baron 1,2
PMCID: PMC8237468  PMID: 34176513

To the Editor,

The Acute Respiratory Distress Syndrome (ARDS) is still associated with high mortality [1], despite application of recent guidelines [2, 3]. The EOLIA study suggested that Extra- Corporeal Membrane Oxygenation (ECMO) could be effective in some of the most severe patients, but failed to demonstrate a 20% increase in survival [4]. One reason could be that criteria for selecting patients were only based on blood gas analysis. Our hypothesis is that adding other factors could allow a better selection of patients who could benefit from ECMO.

We took advantages to have a large multicentric cohort of patients under protective ventilation for moderate-to-severe ARDS [5] to determine the incidence, characteristics and outcome of patients eligible for ECMO according to EOLIA-based criteria and to identify patients who would benefit the most of the technique. ECMO was only used in these centers as a recue therapy.

Mechanical ventilation was applied in the volume-assist control mode, with a target tidal volume (TV) of 6–8 mL/kg (predicted body weight) and a plateau pressure < 30 cmH2O. Respiratory rate could be increased in case of high arterial carbon dioxide partial pressure (PaCO2). Prone positioning was left to the discretion of the attending physician, but was typically performed in patients with a PaO2/FiO2 < 100 mmHg and/or an acute core pulmonale (ACP) [6]. Patients eligible for ECMO according to EOLIA-based criteria were identified as follows: PaO2/FiO2 < 80 mmHg with optimal PEEP, or a pH < 7.25 and PaCO2 > 60 mmHg with a respiratory rate ≥ 35 cycles/min, despite the use of prone positioning or nitric oxide inhalation.

Statistical analysis was performed with R.4.0.4. Patients eligible for ECMO were compared to the rest of the cohort. Continuous data, expressed as medians (interquartile ranges), were compared with Mann–Whitney test. Categorical variables, expressed as numbers and percentages, were compared using the chi-square test or Fisher exact test. To evaluate independent factors associated with ICU mortality in this identified subgroup of patients, significant or marginally significant (p < 0.10) bivariate risk factors were examined using univariate and multivariable backward stepwise mixed logistic regression stratified on the center. SAPS II was forced in the model.

752 patients were studied. Characteristics and outcome are given in the Table 1. 67 (9%) patients were potentially eligible for ECMO. They had lower PaO2/FiO2 (62 [55–72] versus 114 [90–120] mmHg: p < 0.01) and higher incidence of ACP (42% versus 20%, p < 0.001). Only 8 of them underwent the procedure. In-ICU mortality in the whole cohort was 36%. Causes of death in patients eligible for ECMO was multi-organ failure in 21 (68%), neurologic in 4 (13%) and ECMO complication in 3 (10%). Only 3 patients (10%) died from hypoxic cardiac arrest.

Table 1.

Clinical characteristics and outcome of the entire cohort according to EOLIA criteria

Characteristics, outcomes and complications ARDS patients without EOLIA criteria
(n = 685)
ARDS patients with EOLIA criteria
(n = 67)
p-value
Age (years) 59 (47–72) 56 (47–70) 0.43
Male sex, n (%) 465 (68) 42 (63) 0.47
SAPS II 51 (38–65) 47 (33–64) 0.27
Weight (kg) 77 (65–84) 70 (59–86) 0.43
Cause of ARDS, n (%) 0.20
 Pneumonia 83 (12) 8 (12)
 Aspiration 259 (39) 34 (51))
 Non-pulmonary sepsis 245 (37) 17 (26)
 Other causes 83 (12) 7 (11)
Respiratory setting at inclusion
 Tidal volume (ml/kg) 6.7 (6.0–8.0) 6.02 (5.4–6.9)  < 0.01
 Respiratory rate (cycle/min) 22 (16–27) 26 (22–30)  < 0.01
 PEEP (cmH2O) 8 (5–10) 10 (7–12)  < 0.01
 Plateau pressure (cmH2O) 24 (21–28) 27 (25–29)  < 0.01
 Compliance (ml/cmH2O) 30.7 (24–39.1) 25.9 (19.3–33.8)  < 0.01
 Driving pressure (cmH2O) 15 (13–19) 17 (14–19.8) 0.04
Arterial blood gases
 PaO2/FiO2 ratio (mmHg) 114 (90–120) 62 (55–72)  < 0.01
 PaCO2 (mmHg) 44 (38–52) 48 (41–60)  < 0.01
Shock, n (%) 449 (66) 53 (79) 0.04
Prone positioning, n (%) 163 (24) 55 (82)  < 0.01
VV ECMO in rescue during ARDS course, n (%) 0 (0) 8 (12)  < 0.01
RRT during ARDS course, n (%) 126 (30) 15 (40) 0.27
Echocardiographic findings
RVEDA/LVEDA 0.68 (0.57–0.81) 0.83 (0.64–1.04)  < 0.01
 Systolic pulmonary artery pressure (mmHg) 35 (20–48) 52 (35–59)  < 0.01
 Severe acute cor pulmonale 43 (6) 11 (16)  < 0.01
Outcome, n (%)
 ICU mortality 243 (36) 31 (46) 0.10
 ICU stay (days) 16 (8–30) 15 (6–31) 0.43

Values are expressed as median (interquartile range) or n (%)

ARDS, Acute Respiratory Distress Syndrome; PEEP, Positive End-Expiratory Pressure; VV ECMO, Veno-Venous Extracorporeal Membrane Oxygenation; RRT, Renal Remplacement Therapy; RVEDA, Right Ventricular End-Diastolic Area; LVDEA, Left Ventricular End-Diastolic Area; ICU, Intensive Care Unit

Characteristics and outcome of patients potentially eligible for ECMO according to ICU mortality are given in the Table 2. In multivariable analysis, severe right ventricular dilatation (right-to-left ventricle end-diastolic area ratio > 1) and driving pressure were the only factors associated with in-ICU mortality (OR [95% CI]: 5.62 [1.44–27.39], p = 0.02 and 1.14 [1.01–1.31], p = 0.04, respectively).

Table 2.

Clinical characteristics and echocardiographic findings of ARDS patients eligible for ECMO

Characteristics, outcomes and complications Survivors
(n = 36)
Non survivors
(n = 31)
p-value
Age (years) 56 (45–70) 57 (48–70) 0.44
Male sex, n (%) 23 (64) 19 (61) 0.47
SAPS II 44 (32–58) 53 (36–75) 0.15
Weight (kg) 74 (63–97) 67 (56–80) 0.22
Cause of ARDS, n (%) 0.63
 Pneumonia 6 (17) 2 (7)
 Aspiration 18 (50)) 16 (53)
 Non-pulmonary sepsis 8 (22) 9 (30)
 Other causes 4 (11) 3 (10)
Respiratory setting at inclusion
 Tidal volume (ml/kg) 6.3 (5.5–7.6) 5.9 (5.3–6.6) 0.13
 Respiratory rate (cycle/min) 25 (20–27) 30 (25–30)  < 0.01
 PEEP (cmH2O) 10 (8–12) 10 (7–12) 0.72
 Plateau pressure (cmH2O) 26 (24–29) 28 (25–38) 0.07
 Compliance (ml/cmH2O) 30 (2338) 23 (16–28)  < 0.01
 Driving pressure (cmH2O) 16 (14–19) 19 (16–22) 0.05
Arterial blood gases
 PaO2/FiO2 ratio (mmHg) 69 (58–74) 60 (55–67) 0.08
 PaCO2 (mmHg) 48 (40–52) 51 (42–70) 0.17
Shock, n (%) 25 (70) 28 (90) 0.07
Prone positioning, n (%) 31 (86) 24 (77) 0.52
VV ECMO in rescue during ARDS course, n (%) 2 (1) 6 (19) 0.13
RRT during ARDS course, n (%) 9 (33) 6 (55) 0.28
Echocardiographic findings
 RVEDA/LVEDA 0.71 (0.57–0.93) 0.98 (0.71–1.10) 0.10
 Pulmonary hypertension (mmHg) 51 (44–55) 52 (34–63) 0.85
 Severe acute cor pulmonale 3 (8) 8 (26) 0.09
 ICU stay (days) 19 (14–34) 12 (3–20) 0.16

Values are expressed as median (interquartile range) or n (%)

ARDS, Acute Respiratory Distress Syndrome; PEEP, Positive End-Expiratory Pressure; VV ECMO, Veno-Venous Extracorporeal Membrane Oxygenation; RRT, Renal Remplacement Therapy; RVEDA, Right Ventricular End-Diastolic Area; LVDEA, Left Ventricular End-Diastolic Area; ICU, Intensive Care Unit

A limitation of our study is that eight patients of the cohort received ECMO as a rescue therapy, which may have influenced our results, especially since the technique is now safer when performed in expert centers. However, six of these eight patients died.

In conclusion, we report a 9% incidence of patients who reach the EOLIA-based criteria for ECMO in a large non-selected cohort of ARDS patients ventilated with moderate-to-severe ARDS. These patients exhibited higher driving pressure and more frequent right ventricle failure, both being independently associated with ICU mortality. How this subgroup of patients could be considered as the ideal target for ECMO selection strategy should better be evaluated in the future.

Acknowledgements

Not applicable.

Abbreviations

ARDS

Acute Respiratory Distress Syndrome

ECMO

Extra-Corporeal Membrane Oxygenation

TV

Tidal Volume

ACP

Acute Core Pulmonale

PEEP

Positive End Expiratory Pressure

SAPS II

Simplified Acute Physiology Score II

ICU

Intensive Care Unit

RRT

Renal Replacement Therapy

RVEDA

Right Ventricular End-Diastolic Area

LVDEA

Left Ventricular End-Diastolic Area

Authors' contributions

MP and AVB designed the study; AMD, PV, PM, AL collected the data, MP did the statistical analysis, MP and AVB wrote the manuscript; all authors reviewed the manuscript. All authors read and approved the final manuscript.

Funding

None.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declaration

Ethics approval and consent to participate

The study was approved by the Institutional Review Boards of participating centers as a component of standard of care and requirement for patient’s consent was waived.

Consent for publication

Not applicable.

Competing interests

MP, PM, AL, PV declare no competing interest. AMD reports grants from Fischer Paykel, Baxter, and Ferring, and personal fees from Air Liquide, Amomed, and Addmedica, all outside the submitted work. AVB reports research Grant from GSK, outside the submitted work.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788–800. doi: 10.1001/jama.2016.0291. [DOI] [PubMed] [Google Scholar]
  • 2.Fan E, Del Sorbo L, Goligher EC, Hodgson CL, Munshi L, Walkey AJ, et al. An official American Thoracic Society/European Society of Intensive Care Medicine/Society of Critical Care Medicine clinical practice guideline: mechanical ventilation in adult patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 2017;195(9):1253–1263. doi: 10.1164/rccm.201703-0548ST. [DOI] [PubMed] [Google Scholar]
  • 3.Papazian L, Aubron C, Brochard L, Chiche J-D, Combes A, Dreyfuss D, et al. Formal guidelines: management of acute respiratory distress syndrome. Ann Intensive Care. 2019;9(1):69. doi: 10.1186/s13613-019-0540-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Combes A, Hajage D, Capellier G, Demoule A, Lavoué S, Guervilly C, et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965–1975. doi: 10.1056/NEJMoa1800385. [DOI] [PubMed] [Google Scholar]
  • 5.Mekontso Dessap A, Boissier F, Charron C, Bégot E, Repessé X, Legras A, et al. Acute cor pulmonale during protective ventilation for acute respiratory distress syndrome: prevalence, predictors, and clinical impact. Intensive Care Med. 2016;42(5):862–870. doi: 10.1007/s00134-015-4141-2. [DOI] [PubMed] [Google Scholar]
  • 6.Vieillard-Baron A, Prin S, Chergui K, Dubourg O, Jardin F. Echo-Doppler demonstration of acute cor pulmonale at the bedside in the medical intensive care unit. Am J Respir Crit Care Med. 2002;166(10):1310–1319. doi: 10.1164/rccm.200202-146CC. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.


Articles from Critical Care are provided here courtesy of BMC

RESOURCES